Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$6.83 ▲ +0.04
(+0.52%)
MKT CAP: $46.3M • VOL: 57.7K
52W L $6 52W H $18
ROARABLE / RQD
D • 51/100
PIOTROSKI
3 / 9
TIL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$78.6M | -$73.5M | -$159.2M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$71.4M | -$74.1M | -$156.1M |
| EBITDA (Normalized) | — | -$73.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$36.6M | -$55.7M | -$82.0M |
| Capital Expenditures (CapEx) | — | $0 | — |
| Free Cash Flow (FCF) | -$36.6M | -$55.7M | -$82.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -36.2% | — |
| Cash & Short-Term Equivalents | $6.6M | $8.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $113.9M | $169.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TIL.